Lv51
882 积分 2023-04-11 加入
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
1小时前
待确认
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
1小时前
已完结
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial
3天前
已完结
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
1个月前
已完结
Prevalence and risk factors of distant metastasis among Chinese osteosarcoma patients: a systematic review and meta-analysis
1个月前
已关闭
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab
1个月前
已完结
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2个月前
已完结
Emerging landscape of KRAS inhibitors in cancer treatment
3个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
4个月前
已完结
Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies
5个月前
已完结
皖公网安备34019202002308
